


APC/Fire™ 750 anti-human CD45RO


| | |
|-------------------------|---|
| Catalog # / | 2121250 / 100 tests |
| Size: | 2121245 / 25 tests |
| Clone: | UCHL1 |
| Isotype: | Mouse IgG2a, κ |
| Immunogen: | IL-2 dependent T cell line, CA1 |
| Reactivity: | Human, Non-human primate, Other |
| Preparation: | The antibody was purified by affinity chromatography and conjugated with APC/Fire™ |
| Formulation: | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA). |
| Workshop Number: | 750 under optimal conditions. |
| Concentration: | Lot-specific |



Human peripheral blood lymphocytes were stained with CD45RA PE and CD45RO (clone UCHL1) APC/Fire™ 750 (top) or mouse IgG2a, κ APC/Fire™ 750 isotype control (bottom).

Applications:

| | |
|---------------------------|---|
| Applications: | Flow Cytometry |
| Recommended Usage: | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. |



* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

| | |
|---------------------------|---|
| Application Notes: | The UCHL1 antibody is commonly used in combination with antibodies against CD45RA to discern memory and naïve T cells. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections ⁵ and formalin-fixed paraffin-embedded tissue sections ⁴ , Western blotting ² , and immunoprecipitation ³ . |
|---------------------------|---|

**Application
References:**

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. (FC)
 2. Ishii T, et al. 2001. *P. Natl. Acad. Sci. USA* 98:12138. (WB)
 3. Ponsford M, et al. 2001. *Clin. Exp. Immunol.* 124:315. (IP)
 4. Yamada M, et al. 1996. *Stroke* 27:1155. (IHC)
 5. Sakkas LI, et al. 1998. *Clin. Diagn. Lab. Immunol.* 5:430. (IHC)
 6. Baba N, et al. 2010. *Int. Immunol.* 22:237. [PubMed](#)
 7. Thakral D, et al. 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
 8. Weiss L, et al. 2010. *P. Natl. Acad. Sci. USA* 107:10632. [PubMed](#)
 9. Wu YY, et al. 2007. *Infect. Immun.* 75:4357. [PubMed](#)
 10. Mozaffarian N, et al. 2008. *Rheumatology* 47:1335. [PubMed](#)
 11. Roque S, et al. 2007. *J. Immunol.* 178:8028. [PubMed](#)
 12. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
 13. Smith SH, et al. 1986. *Immunology* 58:63. (Immunogen)
 14. Peterson VM, et al. 2017. *Nat. Biotechnol.* 35:936. (PG)
-

Description: CD45RO is a 180 kD single chain membrane glycoprotein. It is a splice variant of tyrosine phosphatase CD45, lacking the A, B, and C determinants. The CD45RO isoform is expressed on activated and memory T cells, some B cell subsets, activated monocytes/macrophages, and granulocytes. CD45RO enhances both T cell receptor and B cell receptor signaling mediated activation. CD45 and its isoforms non-covalently associate with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1 and CD22. CD45 isoform expression can change in response to cytokines.

- Antigen
References:**
1. Thomas M. 1989. *Annu. Rev. Immunol.* 7:339.
 2. Trowbridge I, et al. 1994. *Annu. Rev. Immunol.* 12:85.